CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

June 11, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search